The treatment of carcinoid tumors has traditionally been divided into two approaches. The first aims to remove the tumor or reduce its mass, or at least to stabilize its growth in the presence of ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Eve Perry from Wirral was just 24 years old when she was diagnosed with a rare condition, which had an impact on her whole family and has left her with lifelong scars ...

We decided to stop all antitumor treatment and to continue only with best supportive care. The patient died 31 months after the initial diagnosis. Patients with pulmonary carcinoid tumors can be ...

Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine ... in recent decades. Treatments may include surgery ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The global demand for advanced carcinoid tumor treatments is witnessing a profound acceleration ... This significant leap is attributed to rising incidences of carcinoid tumors, especially in the ...